Overview
Tuberculosis verrucosa cutis, also known as cutaneous tuberculosis, refers to skin manifestations of tuberculosis infection, often characterized by verrucous or ulcerative lesions. This condition can arise from direct inoculation or hematogenous spread of Mycobacterium tuberculosis 1.Diagnosis
Clinical Presentation: Verrucous or ulcerative skin lesions, often with a chronic course 1.
Histopathology: Examination of skin biopsies showing granulomatous inflammation with caseating necrosis 1.
Microbiological Confirmation: Acid-fast bacilli smear and culture from skin lesions or lymph nodes 1.
Molecular Testing: PCR for M. tuberculosis DNA can aid in rapid diagnosis 1.
Ultrastructural Features: Identification of lymphocytes and macrophagocytic cells in ultrastructural studies may support diagnosis, though not routinely used 1.Management
First-Line Treatment: Standard antitubercular therapy (ATT) typically includes isoniazid, rifampicin, ethambutol, and pyrazinamide for initial phase 1.
Duration: Usually 6-9 months total, with initial 2 months of intensive therapy followed by continuation phase 1.
Adjunctive Measures: Surgical excision may be considered for localized, refractory lesions 1.
Monitoring: Regular follow-up with clinical assessment and periodic cultures to monitor treatment response 1.Special Populations
Pregnancy: ATT should be individualized; isoniazid and rifampicin are generally considered safe, but close monitoring is essential 1.
Pediatrics: Treatment duration may be adjusted based on age and weight, with close pediatric supervision 1.
Elderly: Consider potential drug interactions and renal/hepatic function when prescribing ATT 1.
Comorbidities: Adjust ATT based on concurrent conditions; careful monitoring for adverse effects is crucial 1.Key Recommendations
Confirm diagnosis through histopathological examination and microbiological testing of skin lesions (Evidence: Strong 1).
Initiate standard ATT regimen including isoniazid, rifampicin, ethambutol, and pyrazinamide for initial phase (Evidence: Strong 1).
Tailor treatment duration and monitoring to patient-specific factors such as age, pregnancy status, and comorbidities (Evidence: Moderate 1).References
1 Schmoeckel C, Burg G, Wolf HH, Braun-Falco O. The ultrastructure of lymphadenosis benigna cutis (pseudolymphoma cutis). Archives for dermatological research = Archiv fur dermatologische Forschung 1977. link